New Cellular Models For Drug Discovery In Alzheimer?s Disease | 21948
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: It is currently thought that the dementia of Alzheimer?s disease is due to the neurotoxicity of the aggregates or
deposits of amyloid-? (A?) found in the cerebral cortex of patients. As a result the search for therapies has been based on the
development of agents which clear A? in mouse models transfected with mutant genes associated with early onset disease in
humans. A major philosophical problem with these models is that although these mice exhibit many of the pathological and
clinical manifestations of the human disease, individuals with late onset Alzheimer?s disease lack these mutations. Hence,
the question arises whether they are valid models of the late onset disease seen in humans. Furthermore, 11 clinical trials
of drugs that reduced the plaque burden in transgenic mice were found to be ineffective in patients. These finding suggest
that rather than being the cause of the dementia, plaque and soluble aggregates are biomarkers for an age related decline in
the posttranslational, protein processing in the endoplasmic reticulum (ER). This paradigm is supported by our published
observation that in human cerebrospinal fluid there are no aggregates, instead all of the A? is N-glycosylated and bound to two
chaperones, ERp57 and calreticulin. Our data indicate that plaque and aggregates appear when the cell can no longer form this
complex. Since the complex is produced in the ER and most membrane proteins also undergo posttranslational processing in
this organelle, these findings suggest that the dementia seen in Alzheimer?s disease is secondary to a decline in the capacity of
the cell to produce the synaptic membrane proteins that are necessary for memory. Both the activity of the N-glycosylation
pathway and the content of the chaperones in the ER declined with age. These declines may be major factors in the decreased
capacity of the cell to catalyze the posttranslational protein processing in the ER.
Methods: The traditional approach to develop such models is to construct a complex in which the promoter region of the
gene for the target protein is bound to a gene for a reporter protein, such as luciferase. Unfortunately, these constructs fail
to fully identify agents which regulate protein synthesis through cytosolic and nuclear regulatory elements, such as small
RNA?s, histone modifications, epigenetic DNA adducts, protein kinase cascades, variations in the 3?untranslated segment of
the mRNA and cytosolic and nuclear receptors. These cellular components are now known to play major roles in the control
of both transcription and translation.
Results: Author proposes a potentially more robust system in which embryonic stem cells are transfected with fluorescent
proteins, such as GFP, into exons of ER chaperones and one of the 15 MST?s which catalyze the synthesis of the oligosaccharide
complex involved in N-glycosylation.
Conclusions: Such constructs are widely used in cell biology because they only minimally disrupt the structure of the target
protein and have little or no effect on the regulatory elements of the cell. For drug discovery in Alzheimer?s disease the cells
would be transformed into neurons by the addition of the appropriate growth factors. The effect of potential therapeutic agents
on fluorescence would then be determined in microtiter plates after incubation of the cells for hours to days. Major strengths
of this cell based system is that it can identify agents which act through regulatory elements other than the classic promoter
region and would allow rapid screening of large libraries of potential therapeutic agents.
Jordan L Holtzman, Graduated from University of Chicago, the Pritzker School Of Medicine in 1959. He Complete internship from University Ill Rsc/Ed in 1960. He
Completed Residency training from University of Minnesota in 1973, Department of Medicine, University of Minnesota Minneapolis, MN, USA at present he is in
Department of Pharmacology, University of Minnesota Minneapolis, MN, USA. Department of Environmental Health Sciences, University of Minnesota Minneapolis,
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals